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Abstract 
Objective:  An effective human papillomavirus (HPV) vaccine must be accepted by young 
persons in order to achieve its full public health benefits. This study examines the intention to 
receive an HPV vaccine among college age men and women.   
Methods Summary:  340 university students, 138 men and 202 women, ages 18 to 32 (mean 
age of 20.8) completed self-administered questionnaires.  Intention was measured by asking 
participants how likely they would be to accept an HPV vaccine that prevented 1) all HPV, 2), 
cervical cancer but not genital warts, 3), warts but not cancer, or 4) both warts and cancer.   
Results:  Both men and women reported high intent to receive an HPV vaccine, though women 
significantly more so, 77.5% and 88.6% respectively (p < .01).  Men were less willing to receive 
a vaccine that prevents cervical cancer in women (men can transmit HPV to their sexual 
partners) compared to one that prevents cervical cancer and genital warts (34.1% vs.77.5%, p < 
.001).  Intent to receive the HPV vaccine was significantly greater among participants having 
more than five partners compared to those having no partners (OR = 4.4; 95% CI = 1.4, 14.4). 
Intent was also significantly greater among those answering two or three HPV knowledge 
questions correctly compared to those getting none or only one question correct (OR = 3.6; 95% 
CI = 1.3, 9.9).   
 iv 
Conclusions:  A great majority of university students in this study were willing to receive the 
vaccine.  Interest varied according to sexual history and knowledge about HPV, and in men, 
according to whether the vaccine targeted genital warts. 
Public Health Significance: An effective HPV vaccine, and one that is accepted, could have 
enormous public health benefits as vaccinations are one of the most successful public health 
approaches to preventing and controlling many infectious diseases.  
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1.0  INTRODUCTION 
Human papillomavirus (HPV) is one of the most pervasive sexually transmitted diseases (STDs) 
in the United States as 20 million people are currently infected with HPV and an estimated 6.2 
million Americans will acquire a new HPV infection each year (Centers for Disease Control and 
Prevention [CDC], 2006a).  Of the estimated 15.4 million new cases of STDs in the Unites States 
prior to 1996, HPV made up the largest portion with 5.5 million cases (Burk et al., 1996).  
Epidemiologic studies suggest that 75% of all people who are sexually active will become 
infected with HPV at some point in their lives (Koutsky, 1997).  An estimated 50% of all 
reported cases of STDs are among people 15 to 24 years of age (Weinstock, Berman, & Cates, 
2000) and the highest rate of HPV infection are among adults ages 18 to 28 (Koutsky, 1997).   
Although less is known about HPV among men, research suggests that levels of current 
infections in men appear to be similar to the levels in women (CDC, 1999). HPV infection tends 
to be transient, asymptomatic and causing no clinical problems, but may manifest as genital 
warts in both men and women, or cervical cancer in women.   Approximately 1% of the sexually 
active population in the U.S. aged 15 to 49 has genital warts (Koutsky, Galloway, & Holmes, 
1988) while research in both the U.S. and Europe suggests that the highest incidence of genital 
warts is among men and women 20 to 24 years of age (Chuang, Perry, Kurland, & Ilstrup, 1984; 
Persson & Krantz, 1996; Simms & Fairley, 1997).  Approximately 500,000 new cases of cervical 
cancer occur each year worldwide, 260,000 of which are fatal (CDC, 2006b).  In the U.S., it is 
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estimated that there were over 9,700 cases of cervical cancer in 2006, and of these 3,700 resulted 
in deaths (American Cancer Society [ACS], 2005; CDC, 2006b).   
Vaccinations are one of the most successful public health approaches to preventing and 
controlling many infectious diseases.  At the end of 2005 Merck and GlaxoSmithKline each 
announced that its experimental HPV vaccine, Gardasil and Cervarix respectively, were 100% 
effective in preventing the infection of HPV strains 16 and 18 in women over five years time, 
which together cause about 70% of cervical cancers.  Merck also announced that Gardasil was 
99% effective in preventing HPV strains 6 and 11, which together cause about 90% of genital 
warts (Kaiser Family Foundation, 2006).  Determining the acceptability of the HPV vaccine is 
very important as HPV is a sexually transmitted disease that is not only detected in almost 100% 
of cervical cancers worldwide (Walboomers, et al., 1999) but also strains of the virus have been 
linked to 70% of anal cancers and 70% of precancerous lesions of the penis (Geipert, 2005).  A 
goal of Healthy People 2010, objective 25-5, is to decrease the number of HPV infections (U.S. 
Dept of Health and Human Services, 2000).  An effective HPV vaccine, and one that is accepted, 
could have enormous public health benefits for both men and women by decreasing the 
morbidity and mortality associated with cervical, anal, and penile cancers, which may translate 
into enormous savings in healthcare costs as well as the emotional and financial costs associated 
with cancer and genital warts.    
Previous research on the acceptability of an HPV vaccine has focused primarily on 
adolescent females and parental views of these adolescent females receiving the vaccine.  Results 
have shown that a large proportion of females studied, as well as parents of adolescent females, 
would accept an HPV vaccine were it available (Boehner, Howe, Bernstein, & Rosenthal, 2003; 
Hoover, Carfioli, & Moench, 2000;  Kahn, Rosenthal, Hamann, & Bernstein, 2003; Mays, 
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Sturm, & Zimet, 2004; Olshen, Woods, Austin, Luskin, & Bauchner, 2005; Zimet, Mays, 
Winston, et al., 2000; Zimet, et al., 2005).  The CDC’s Advisory Committee on Immunization 
Practices (ACIP) recommends the vaccine for girls as young as age nine, and it also recommends 
the vaccine for females up to age 26 (Kaiser Family Foundation, 2006).  The upper age limit was 
set because at the time of this study the vaccine has only been tested in females up to age 26.  
Though the vaccine will be most effective if received before the onset of sexual activity, 
vaccination is recommended for those already sexually active as well, regardless of a previous 
history of HPV infection or an abnormal Pap test, as there do not appear to be any adverse 
effects in vaccinating women with prior infection and because women infected with one type of 
HPV are still at risk for infection with other types.   
Research has found that college women  (ages 18 to 23) have a greater risk of acquiring 
STDs than the general population because of the high-risk sexual behaviors in which they engage 
(Burak & Meyer, 1997) and one study found that as many as 60% of college-age women had 
some strain of HPV (Alvey, 1995).   Thus, it is very important to understand how college age 
individuals view the vaccine since they are at the age when they, not their parents, will need to 
make the decision to get the vaccine.  A study by Mays, Sturm, and Zimet (2004) found that 32 
of the 34 parents they surveyed expected their child to make his/her own decision regarding 
vaccination by age 18.  Vaccine acceptability among older adolescents and young adults is also 
important as vaccine distribution will need to play catch up in the first few years and target older 
individuals as well.  College health services will need to consider methods to get the vaccine to 
students, many of whom do not have traditional health insurance.  
To date recommendations for use focus on women.  National vaccine recommendations 
have not yet been made for men, but research on the efficacy of the vaccine in males has recently 
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begun.  The safety and efficacy of the HPV vaccine have recently been established for males 
aged 9 to 15 years, though additional clinical trials are still needed (Friedman, Kahn, Middleman, 
Rosenthal, & Zimet, 2006).  
Understanding men’s views of the vaccine and how these compare to women’s is crucial 
to the elimination of cervical, penile, and anal cancers, as well as genital warts.  Little prior 
research has examined men’s intent to receive an HPV vaccine compared to women’s.  Focusing 
on women only sends the message to both men and women that prevention of HPV is 
exclusively a woman’s problem.  Men play a considerable role in the transmission of HPV as 
findings reveal that men with HPV report significantly more sex partners than those without the 
infection and women who have had at least one new partner since their last visit to the clinic 
were at an increased risk for HPV if their partners had multiple partners (Hippelainen, et al., 
1993; Ho, Beirman, Beardsley, Change, & Burk, 1998).  Therefore, the willingness of men to 
receive the vaccine is important not only for the men themselves, but also may have an indirect 
health benefit for women by significantly decreasing their risk of acquiring HPV.   
Studies by Bosch et al. (1996) and Burk et al. (1996) conducted with married couples 
showed that risk for cervical cancer is strongly associated with the number of partners a 
woman’s husband has had, as well as the number of past partners of the woman herself.  
Researchers found an increased risk of cervical cancer in female partners of men infected with 
HPV (Bosch, et al., 1996; Hippelainen, et al., 1994; Zunzunegui, King, Coria, & Charlet, 1986).  
Clustering has been found of female and male genital cancers as well as an increased risk of 
cervical cancer among wives of men with penile cancer whose previous wife died of cervical 
cancer, and of men with a high number of sexual partners (Agarwal, Sehgal, Sardana, Kumar, & 
Luthra, 1993; Brinton, et al., 1989; Buckley, Harris, Doll, Vessey, & Williams, et al., 1981; 
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Pridan & Lilienfeld, 1971; Slattery, et al., 1989; Thomas , et al., 1996; Zunzunegui, King, Coria, 
& Charlet, 1986).   
Men often have more partners and due to the lack of testing and the absence of symptoms 
they often do not know they have the infection (Hippelainen, et al., 1993). Vaccinating both 
genders would prevent the transmission of the virus between men and women as well as prevent 
placing the issue solely in women’s hands.    
The vaccine’s target diseases (i.e.,  cervical cancer, or genital warts and cervical cancer)  
and which target diseases are emphasized when promoting the vaccine are important to examine 
as this may determine the acceptability of the vaccine by gender.   An HPV vaccine that is 
marketed as preventing both cervical cancer and genital warts may be better received among 
young men, thus increasing its use among both sexes.  Lastly, knowledge about HPV may vary 
by gender, greatly affecting interest in the vaccine.  
1.1 HPV INFECTION 
Over 30 strains of HPV exist that infect the genital area and are spread by skin-to-skin contact 
during sex (Daley, 1998; International Agency for Research on Cancer [IARC], 1995; Koutsky, 
1997).  Genital HPV infections are categorized by their association with cervical cancer.  Two 
HPV strains, types 6 and 11, categorized as low-risk types, can cause benign cervical cell 
changes and cause nearly all male and female genital wart infections.  Approximately 20 HPV 
strains can cause cervical cancer in women; four are accountable for the majority of cases, 
known as high-risk types.  Types 16 and 18 together cause about 70% of cervical cancer, and 
Types 31 and 45 together cause another 15% (IARC, 1995).  Infection with high-risk HPV is 
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also associated with the growth of other malignancies including oral, vulvar, penile, and anal 
cancers (Castle, et al., 2004; Daling, et al., 2004; Gilson & Lowy, 2004).  Frisch found that about 
90% of anal cancers among women, 58% among heterosexual men, and 100% among 
homosexual men were positive for high-risk HPV DNA (Frisch, 2002).  The association of HPV 
of the genitals with non-genital cancers (i.e., head, neck, & esophageal cancers) has been less 
well established, but studies do support the possibility (Herrero, et al., 2003; Syrjanen, 2002).   
HPV infections typically occur during the first few years of sexual activity, among 
adolescents or those in their early twenties (Berkow, Beers, & Fletcher, 1997; IARC, 1995).  
Research has revealed that the median duration of the new infection is normally eight months; 
about 70% of new infections clear up within one year and 91% clear within two years (Franco, et 
al., 1999; Ho, Bierman, Beardsley, Chang, & Burk, 1998; Molano, et al., 2003; Moscicki, et al., 
1998).  HPV-16 tends to persist longer than other types, though most are undetectable within two 
years (Ho, Bierman, Beardsley, Chang, & Burk, 1998).   
Many factors have been found to be associated with persistence of HPV infection, 
including older age, high-risk HPV types, infection with multiple HPV types, and immune 
suppression (Hildesheim, et al., 1994; Ho, et al., 1995).  Rates of HPV infection spontaneously 
resolving on its own or progression to cervical cancer without treatment vary for low-grade and 
high-grade cervical cell abnormalities.  Low-grade cervical cell abnormalities typically resolve 
spontaneously (60%) and rarely progress to cancer (1%).  Without treatment, high-grade cervical 
cell abnormalities spontaneously resolve much less often (30-40%) and progress to cancer 
without treatment much more often (12%) (Ostor, 1993).  Co-factors that appear to be necessary 
for the development of cancer in addition to a persistent infection are long-term use of oral 
contraceptives,  high number of live births, and co-infection with other STDs like Chlamydia, 
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herpes simplex virus-2 or genital herpes (Castle & Giuliano, 2003; Castellsague, Bosch, & 
Munoz, 2002; Castellsague & Munoz, 2003; Hildesheim, et al., 2001; Munoz, 2000; Munoz & 
Bosch, 1989; Sedjo, et al., 2003; Smith, et al., 2002; Smith, et al., 2003).   
Progression to cervical cancer may not occur for 20 or more years after the first infection 
with HPV occurs, while genital warts normally appear one to six months later (IARC, 1995; 
Koutsky, 1997).  Since cervical cancer typically occurs later in life (ages 35 and above) (Berkow 
Beers, & Fletcher, 1997; IARC, 1995), adolescents may be less concerned about HPV infection, 
and therefore protection from it than they are about acquiring genital warts or another STD. 
While introduction of the Pap test has lowered the incidence of cervical cancer by about 
75%, Pap tests detect only about 90% of cervical cancers (ACS, 2003; Koutsky, 1997).   In the 
United States, an estimated 40% of women do not have regular Pap testing and in developing 
countries Pap testing just is not viable. Current cervical cancer treatment is not completely 
satisfactory and genital warts never entirely go away.  Due to the fact that HPV infections can 
stay subclinical for many years, the spread of HPV cannot be halted merely by treatment of the 
disease, or by abstaining from sex during active periods of the disease.  Condoms have been 
found to have limited effectiveness in preventing the transmission of HPV as it can be spread 
merely by skin contact (Koutsky, 1997).  Prevention has been extremely challenging since HPV 
is highly contagious and because men typically are not screened for HPV (IARC, 1995; Koutsky, 
1997; Ralefsky & Barraasso, 1996).   
Costs associated with HPV may be significantly reduced with the implementation of a 
vaccine.  A study of women in a U.S. health care plan estimated that on average, $26,415 was 
spent per 100 women in cervical screening and treatment for HPV-related diseases. 
Extrapolating this data to the general U.S. population, it is estimated that annual healthcare costs 
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related to HPV were estimated to be $3.4 billion in 1998.  About 90% of the estimated costs was 
attributed to cervical cancer prevention (i.e., treatment for precancerous lesions and routine Pap 
tests), while the other 10% was used on the treatment of cervical cancer.  An annual cost of 
$51,863 was spent per 100 women ages 20 to 29 on HPV related healthcare (Insinga, Glass, & 
Rush, 2004).  An estimated $2.9 billion is spent on total lifetime medical costs of HPV infection 
for men and women ages 15 to 24, making it the second most expensive STD after HIV.  
Concerning genital warts alone, based on an incidence of 500,000 cases in 2000, the annual 
direct medical cost of all age groups was $167.4 million (Chesson, Blandford, Gift, Tao, & 
Irwin, 2000).  The transmission of HPV from mother to child during birth may cause the growth 
of warts in the upper respiratory tract of an affected child, which can cause significant upper 
airway problems that may require multiple surgeries, leading to additional healthcare costs 
(Bergler & Gotte, 2000; Silverberg, Thorsen, Lindeberg, Grant, & Shah, 2003).  While 
psychological costs due to HPV may be difficult to measure in terms of a dollar amount, it is 
evident that distress, anxiety, concern, and embarrassment do exist (Basen-Esgquist, et al., 2003; 
Bell, et al., 1995; Campion, et al., 1988; Chandler, 1996; Lerman, et al., 1991; Maissi, et al., 
2005; Persson, Dahlof, & Krantz, 1993). One report found that a diagnosis of genital warts is 
often the most anxiety-provoking of HPV infections (Baer, Allen, & Braun, 2000). 
1.2 HPV KNOWLEDGE 
Insufficient consideration has been given to promoting primary prevention of HPV.   Previous 
research has found that knowledge of HPV in the United States is minimal among adolescents, 
undergraduate students, and even women who have had an abnormal Pap smear and were 
 8 
referred for further testing (Biro, Rosenthal, Kollar, & Hillard, 1997; Dell, Chen, Ahmad, & 
Stewart, 2000; Holcomb, Bailey, Crawford, & Ruffin, 2004; Horn, McQuillian, Ray, & Hook, 
1990; Jennings, 1997; Jubelirer, et al., 1996; Masad, Meyer, & Hobbs, 1997; Mays, et al., 2000; 
Pitts & Clarke, 2002; Ramirez, Ramos, Clayton, Kanowitz, & Moscicki, 1997; Sharp, Dignan, 
Dammers, Michielutte, & Jackson, 1990; Waller, et al., 2003).  Other recent studies have found 
that adolescent and adult women who have heard of HPV report high rates of misunderstanding 
about the disease, its related conditions, the link of cervical cancer with an abnormal Pap test, 
and the function of cervical cancer screening (Dell, Chen, Ahmad, & Stewart, 2000; Goldie, et 
al., 2004; Harper, 2004; Holcomb, Bailey, Crawford, & Ruffin, 2004; Kulasingam & Myers, 
2003; Mays, et al., 2000; Pitts & Clarke, 2002; Taira, Neukermans, & Sanders, 2004; Waller, et 
al., 2003; Zimet, Mays, & Fortenberry, 2000).   
Dell and colleagues (2000) reported that only 13% of adolescents had heard of HPV in 
their study conducted in Canada.  Holcomb, Bailey, Crawford, and Ruffin (2004) reported that of 
patients attending university and family practice clinics in the United States, 67% had heard of 
HPV.  Baer, Allen, and Braun (2000) found that among first-year college students awareness and 
concern about STDs in general had increased among both males and females, but this increase in 
knowledge has not extended to HPV.  Roughly 96% of both male and female students had heard 
of genital warts, but only 4.2% of males and 11.6% of females knew that HPV caused genital 
warts. The majority of students knew little about HPV infection, its transmission, and the 
prevalence of HPV relative to other common STD’s.   
A survey by Hoover, Carfioli, and Moench (2000) revealed that 34.5% of female 
respondents ages 18 and older had heard of HPV, while only 8.3% of those ages 17 and under 
had heard of the infection.  Most of the respondents who heard of HPV did so at school (14.8%), 
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while only 9% heard of the infection from their doctor, and the same number informed by 
television (Hoover, Carfioli, & Moench, 2000).  Studies in the United Kingdom found that only 
about 30% of women had heard of HPV, and experience with an abnormal Pap smear result was 
predictive of greater knowledge of HPV (Pitts & Clarke, 2002; Waller, et al., 2003).  This is 
worth noting since it suggests that women were only educated about HPV once they have 
already experienced the infection.  
Though research has shown that men are unaware of the link between HPV and cervical 
cancer (Baer, Allen, & Braun, 2000; Dell, Chen, Ahmad, & Stewart, 2000; Lambert, 2001; 
Yacobi, Tennan, Ferrante, Pal, & Roetzheim, 1999), other studies have found that men are 
willing to make positive behavioral changes should they understand the consequences of the 
disease (McPartland, Weaver, Lee, & Koutsky, 2005).  The higher the understanding of HPV 
and its consequences, the higher the intention to decrease the number of sex partners.  Over half 
of the men (53.7%) reported they would reduce the number of new sex partners if they were 
diagnosed with HPV and almost all (95%) indicated that they would use condoms with new 
partners.  General knowledge of HPV infection was also associated with intention to encourage 
female sex partners to undergo Pap smear screening.  These findings reveal that including men in 
HPV education and prevention can be very valuable.   
The findings of Baer and colleagues (2000) suggest that both young men and women 
would like more information about STDs but either the information is not getting to them or the 
information they do receive is not presented clearly or  is not easily accessible.   It is important to 
note that these authors found that the main source of STD information for both male and female 
respondents was health education classes in middle or high school.  The abundance of findings 
that knowledge about HPV is so limited suggests that negligible efforts have been made to 
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inform individuals, particularly men, about HPV.  This reinforces the notion that additional 
information concerning HPV needs to be disseminated and the involvement of adolescents and 
young adults in the creation of sex education interventions and prevention strategies would be 
beneficial.  Programs developed by health professionals without input from the population most 
at risk of infection may not be doing the job.  Redesigning curricula to involve the information 
adolescent and young adults want and need to know, as well as how they feel it is best delivered, 
may be more effective.   
1.3 HPV VACCINE ACCEPTANCE 
Previous research concerning other STD vaccines in development, such as HIV and genital 
herpes, suggests that vaccine acceptability should not be taken for granted (Barie, Dellinger, 
Dougherty, & Fink, 1994; Fedson, 1994; Liau, Zimet, & Fortenberry, 1988; Rosenthal, 
Kottenhahn, Biro, & Succop, 1995; Wood, Pereyra, Halfon, Hamlin, & Grabowsky, 1995; 
Zimet, et al., 1997; Zimet, Liau, & Fortenberry, 1997).  Even for non-STDs, vaccine acceptance 
has been low (Fedson, 1987). Thus, given the shame and stigma incurred by STDs, additional 
opposition to STD vaccinations is likely (Zimet, et al., 1997). 
Numerous studies of already existing vaccines shown to be safe and effective (e.g., 
influenza, hepatitis B) report inadequate vaccination acceptance among those most at risk for the 
very conditions vaccines would protect against (Barie, Dellinger, Dougherty, & Frank, 1994; 
Bates, Fitzgerald, Dittus, & Wolinsky, 1994; CDC, 1998; Fedson, 1994; Zimet, Kee, Winston, 
Perkins, & Maharry, 2001).  Failure to get recommended immunizations is seen in even high-risk 
professional groups like doctors and nurses (Barie, Dellinger, Dougherty, & Fink, 1994).  
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Reasons reported for not getting immunized for hepatitis B are low perceived susceptibility, 
concern over vaccine efficacy and safety, general inertia, and fears about getting injections 
(Barie, Dellinger, Dougherty, & Fink, 1994; Bodenheimer, Fulton, & Kramer, 1986; Crossley, 
Gerding, & Petzel, 1985; Israsena, Kamolratanakul, & Sakulramrung, 1992; Lettau, Blackhurst, 
& Steed, 1992; Manian, 1991; McKenzie, 1992; Mundt, 1992;  Scapa, Karpuch, Waron, & 
Eshchar, 1989).  Zimet, Liau, & Fortenberry (1997) found that only 30% of respondents opposed 
getting an HIV vaccine.  Susceptibility, perceived benefits, pragmatic obstacles, conditional 
nonmembership in a risk group, and fear of the vaccine demonstrated significant independent 
predictive power of intention to get vaccinated against HIV.  
Many of the previously stated reasons for not getting vaccinated are related to aspects of 
the Health Belief Model (HBM), which postulates that individuals will engage in preventive 
behaviors if they believe themselves to be at risk of contracting a particular condition and if the 
benefits of preventive actions outweigh the barriers to, or costs of, such actions (Glanz, Rimer, & 
Lewis, 2002).  The HBM has been used successfully to predict vaccine acceptance for various 
conditions, including influenza, poliomyelitis, and hepatitis B (Bodenheimer, Fulton, & Kramer, 
1986; Frank, Henderson, & McMurray, 1985; Oliver, & Berger, 1979; Rosenstock, Derryberry, 
& Carriger, 1959).  
Recent research suggests there are various factors likely to affect successful 
implementation of future immunization programs designed to prevent STDs (Zimet, Mays, & 
Fortenberry, 2000).  One factor found to affect vaccine acceptance in the past, at least in the 
United States, is social or moral grounds.  That is, individuals have claimed that STDs are 
suitable punishment for premarital sexual behavior and effective STD prevention may reduce the 
deterrent to engage in premarital sexual activity, thus feeling it will lower their social and moral 
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values (Brandt, 1985).  However, due to recent HIV education in the U.S., there is some 
indication that this STD stigma has lessened (Herek, Capitanio, & Wideaman, 2002).  
Other factors related to STD vaccine acceptance are associated with various health 
beliefs, particularly perceived susceptibility to infection, perceived benefits of getting the 
vaccine, barriers to vaccination, and social norms (Liau & Zimet, 2000; Rosenthal, Kottenhahn, 
Biro, & Succop, 1995; Rosenthal, Lewis, Succop, Bernstein, & Stanberry, 1999; Zimet, et al., 
1997; Zimet, Liau, & Fortenberry, 1997).  Choosing to get immunized for an STD implies 
acknowledgement that one is at risk for acquiring an STD.   Adolescents and college-aged males 
and females, on average, do not consider themselves vulnerable to STDs (Baer, Allen, & Braun, 
2000; Dell, Chen, Ahmad, & Stewart, 2000; Ramirez, Ramos, Clayton, Kanowitz, & Moscicki, 
1997; Yacobi, Tennan, Ferrante, Pal, & Roetzheim, 1999), and thus are not apprehensive about 
HPV (Baer, Allen, & Braun, 2000; Dell, Chen, Ahmad, & Stewart, 2000).  
Previous research has shown that acceptance of an HPV vaccine is associated with 
vaccine efficacy, cost, physician recommendation, positive beliefs about vaccines, and 
knowledge (Davis, Dickman, Ferris, & Dias, 2004; Kahn, Rosenthal, Hamann, & Bernstein, 
2003; Rosenthal, Kottenhahn, Biro, & Succop, 1995; Zimet, Mays, Winston, et al., 2000).  
Another study found that the best predictor of adolescent acceptance of the hepatitis B vaccine 
was their perception that their parents felt the vaccination was important (Rosenthal, Kottenhahn, 
Biro, & Succop, 1995).    
Vaccine acceptance among physicians and various health care providers is also essential 
to the success of vaccine implementation. Research suggests that HPV vaccine acceptance is 
high among physicians, though various factors affect recommendation.  Riedesel, et al. (2005) 
found that family physicians were significantly more likely to recommend the vaccine to girls 
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and older adolescents than they were to boys and younger adolescents.  Physicians were more 
likely to recommend the vaccine to boys and girls if it prevented against cervical cancer and 
genital warts versus cervical cancer alone.  Gender of the provider (female), higher knowledge 
about HPV, and positive attitudes about vaccination were independently and positively 
associated with physicians’ intention to recommend an HPV vaccine.  Though most of the study 
respondents did report a high level of comfort addressing issues of sexuality, a finding that 
differs from other studies (Haley, Maheux, Rivard, & Gervais, 1999; Maheux, Haley, Rivard, & 
Gervais, 1995), the authors speculate that a provider’s unwillingness to vaccinate young 
adolescents may be because of feeling uneasy discussing matters of sexuality with young teens 
or their parents or a belief that young adolescents are not at immediate risk for HPV.  They did 
find that those who reported discomfort addressing sexuality issues had lower intention to 
recommend the vaccine.  
Another study by Raley, Followwill, Zimet, and Ault (2004) found that the most 
important factor in vaccine administration among gynecologists was American College of 
Obstetricians and Gynecologists (ACOG) recommendations, followed by vaccine efficacy, age, 
and disease targeted.  Concerning the disease targeted, gynecologists were more likely to 
recommend a vaccine that prevented against cervical cancer, or cervical cancer and genital warts 
than one that prevented against genital warts alone. Unlike the findings by Riedesel et al. (2005), 
Raley and colleagues found that demographic characteristics of the gynecologists, including age, 
gender, practice setting, and community setting, did not play a pivotal role in their decisions 
regarding the vaccine. 
The previously mentioned findings concerning gynecologists and obstetricians are 
noteworthy, though the low response rate has been a major dilemma.  In they study by Riedesel 
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and colleagues (2005), which randomly distributed surveys to 1,000 American Academy of 
Family Physicians (AAFP) members, only 155 surveys were returned (15.5%) and only 145 
were used in the analysis. Raley et al. distributed their surveys to 1200 Fellows of ACOG though 
only 181 (15.1%) surveys were returned and included in their analysis.  Such low response rate 
leads to caution in generalizing their results.     
1.4 GENDER DIFFERENCES 
Very few studies have actually assessed men’s acceptance of an HPV vaccine.  McPartland, 
Weaver, Lee, and Koutsky (2005) examined young men’s perceptions of HPV.  Though they did 
not assess intention to receive an HPV vaccine, results showed that understanding that HPV may 
have severe consequences for women was associated with men’s intention to reduce their 
number of sex partners.  Vaccinating both genders would help to prevent the transmission of the 
virus between men and women as well as prevent putting responsibility for prevention solely on 
the women.   
Due to differences in the views on STDs and healthcare by gender, differences in vaccine 
acceptance may also differ by gender.  Women were found to be more knowledgeable about 
genital herpes and susceptibility to STDs, while they also reported more negative reactions to 
becoming infected and greater concern over parents’ reactions to the infection as compared to 
men (Lewis, Bernstein, Rosenthal, & Stanberry, 1999).  Men and women also differ when it 
comes to seeking healthcare for numerous illnesses, such as diabetes, tuberculosis, and 
psychiatric disorders.  Men tend to go for care only when their symptoms are more severe, thus, 
often after they have fully developed (Albizu-Garcia, Alegria, Freeman, & Vera, 2001; Hjelm, 
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Nyberg, & Apelqvist, 2002; Johansson, Long, Diwan, & Winkvist, 2000). Women are more 
preventative, seeking routine care to stop the problem before it occurs, or seeking care before the 
problem progresses. Women also tend to worry more about their health and that of their partners 
(Aten, Siegal, & Roghmann, 1996; Norcross, Ramirez, & Palinkas, 1996).  These differences 
may extend to vaccine acceptability, affecting the decision making process of men and women.  
A study by Hoover, Carfioli, and Moench (2000) found that almost 95% of the women they 
surveyed felt men should be vaccinated against HPV to prevent transmitting the infection to their 
partners, and 100% felt that men should receive a vaccine against HPV if the vaccine would also 
protect men against genital warts.   
Others have investigated whether there is a difference between men and women in STD 
vaccine acceptability but have found no differences (Liau & Zimet, 2000; Rosenthal, Lewis, 
Succop, Bernstein, & Stanberry, 1999; Zimet, et al., 1997; Zimet, Kee, Winston, Perkins, & 
Maharry, 2001). However, these studies looked at the rates of acceptance, not the reasons why or 
why not by gender.  Auslander et al. (2005) explored whether there were gender differences in 
the role of health beliefs (perceived severity, perceived susceptibility, barriers, and social 
influence) on acceptance of a genital herpes vaccine.  A history of an STD and high perceived 
risk of becoming infected with genital herpes were significant predictors of vaccine acceptance 
for men, while younger age and vaccine safety concerns were significant predictors for women.  
These findings imply that health-care messages concerning STD vaccines need to take gender 
into consideration. 
Thus, the overall aim of this research project is to assess the intent to receive an HPV 
vaccine among students attending an urban university by exploring age and gender of those 
willing and not willing to receive the vaccine as well as differences in preferences for potential 
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vaccine attributes.  It is hypothesized that 1) women will be more willing than men to receive an 
HPV vaccine, 2) younger students will be more willing to accept an HPV vaccine that prevents 
genital warts as compared to one that prevents cervical cancer alone, and 3) men will be more 
willing to receive an HPV vaccine that prevents genital warts.  
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2.0  METHODS 
2.1 STUDY DESIGN 
In this cross-sectional study participants were recruited by convenience sampling at the 
University of Pittsburgh in Pittsburgh, Pennsylvania.  The majority of recruitment was conducted 
at the university’s Student Health Services while some surveys were distributed in two 
undergraduate psychology courses, Health Psychology and Research Methods.  The study was 
completed several months prior to actual availability of the vaccine.  The study was approved by 
the University of Pittsburgh’s Institutional Review Board and was completely anonymous, thus 
written informed consent was not obtained.   
The researcher approached students individually while they were sitting in the Student 
Health Services waiting room explaining who she was, where she came from, and what the study 
was about.  She went on to tell participants the survey was completely voluntary and anonymous, 
and should they decide to complete the questionnaire, their honesty was very important and 
greatly appreciated.  Lastly, she asked each of them to be sure to read the instructions carefully 
and then when done, to place the survey in the envelope provided so that their answers would 
remain confidential and anonymous.  The same information was provided collectively to 
students who completed the survey during class time, in addition to an emphasis on the fact that 
their participation would have no bearing on their standing in class. Students did not put their 
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name on the survey, thus they were completely anonymous. Participants received a $1 lottery 
ticket as a token of appreciation for completing the survey.   
2.2 SAMPLE 
Three hundred and fifty-five university students were asked to complete the five to 10 minute 
self-administered questionnaire containing 34 questions.  Over a one month time period (April of 
2006) 340 surveys were completed at the three sites; nine refused and six were returned 
incomplete.    
2.3 MEASURES 
Validated measures of attitudes regarding acceptance of an HPV vaccine do not exist; thus, 
theory and related articles were utilized to develop items specific to this topic (Rosenthal, Lewis, 
Succop, Bernstein, & Stanbery, 1999).  Initial items were reviewed by experts in the field and 
several college students and then modified to enhance brevity, clarity, and understanding.  
Vaccine intent was assessed by describing specific vaccine attributes and was measured 
by having the participants answer the following questions: “Assuming the HPV vaccine was 
available now, how likely would you be to get the vaccine if 1) it prevented all HPV, 2) it 
prevented cervical cancer in women, but did not prevent genital warts, 3) it prevented genital 
warts, but did not prevent cervical cancer, and 4) it prevented both genital warts and cervical 
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cancer.”  The response options given were a 5-point Likert scale ranging from “Extremely 
likely” to “Extremely unlikely”.   
The survey also assessed demographics, sexual history, perceived and actual knowledge 
of HPV, and lastly attitudes and perceived health beliefs.  Perceived knowledge was assessed 
after giving the participants a brief statement describing HPV.  The statement read “HPV is a 
sexually transmitted virus that can cause genital warts or cancer”.  Participants were then asked, 
“How knowledgeable would you describe yourself when it comes to Human Papillomavirus or 
HPV?”  Actual knowledge was measured by asking the participants to agree or disagree with 
three statements; “HVP can be asymptomatic” (True), “HPV can spontaneously resolve 
completely without treatment” (True), and “Greater than 50% of sexually active college students 
will have HPV once during college” (True).   A sum score of 0 to 3 was then computed and those 
with a score of 2 or 3 were classified as knowledgeable.     
Perceived susceptibility was assessed by asking what the participants thought their 
chances of getting HPV sometime in their lives were as well as their chances of getting a 
complication from HPV should they become infected.   The response options for each were “0-
20%”, “21-40%”, “41-60%”, “61-80%”, and “81 to 100%”. Perceived severity was assessed by 
asking participants to agree or disagree with the following statement; “HPV is not serious 
enough for a vaccine” and “How upset would you be if you were told that you: a) have genital 
HPV but you have no symptoms and b) have genital warts?”  Participants chose from answers on 
a 5-point scale of “worst thing that could happen” to “not at all upset”.  Participants were also 
asked, “How severe do you think genital HPV infection is for yourself?”   We also assessed 
whether perceived norms, specific recommendations, or costs would lead persons to be more or 
less likely to accept the vaccine, using a 7-point scale ranging from “much more likely to accept” 
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to “much less likely to accept”.  Specifically, persons were asked whether the following would 
make him or her more or less likely to get the vaccine, “friends and family would know that I got 
the HPV vaccine” and “the HPV vaccine was recommended to me by my a) doctor, b) 
spouse/partner, c) friends, and d) parents”.  Attitudes about cost were also assessed by asking 
whether “Having to pay $50 for the HPV vaccine myself” and “Having the HPV vaccine be free” 
made the participants more or less likely to get the vaccine. 
2.4 DATA ANALYSIS 
Data analysis was conducted using the Statistical Package for the Social Sciences, 14.0 for 
Windows (SPSS Inc., Chicago, IL).  The main outcome measure, intent to receive an HPV 
vaccine, was dichotomized into “Extremely or somewhat likely” and “Not likely, Somewhat 
unlikely, or Unsure”.  Comparisons were then made by gender via chi-squared tests with the 
statistical significance level set at p ≤ .05.  Analyses of intent to receive an HPV vaccine were 
also conducted by the specific vaccine attributes: preventing “all HPV” and “both genital warts 
and cervical cancer”.  Responses were similar in both men and women, thus during the final 
analyses we chose to look only at the responses to the question when worded as “both genital 
warts and cervical cancer”. Multivariate logistic regression analyses were also performed to 
assess the relationship of demographics, sexual and STD history, knowledge, and attitudes to 
vaccine acceptance.   
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3.0  RESULTS 
3.1 DESCRIPTIVE ANALYSIS 
The study sample consisted of 340 university students, 138 males and 202 females, ages 18 to 32 
(mean age =20.8).  Participants were mostly white, 82.6%, and a majority of the surveys were 
completed at the Student Health Center (65%).   More than half of the participants, 67.1%, were 
currently dating (one steady partner or no specific partner) and 32.9% were not dating, married, 
or living with someone. One-fourth of the participants, 24.8%, reported never having sexual 
intercourse and of the rest (75.2%), 18.2% had one partner, 37.8% had two to five partners and 
22.6% had more than five partners.  Few (9.4%) reported ever having a sexually transmitted 
disease, while 6.8% reported having HPV and 1.2% reported having genital warts.  About three-
fourths, 66.5%, of the participants got zero or one of the three knowledge questions correct, and 
82.4% perceived themselves as either somewhat knowledgeable of HPV or not at all 
knowledgeable.  See Table 1 for a further breakdown by gender. 
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Table 1 Characteristics of Study Population by Gender 
Variable Male  
n = 138 
n (%) 
Female  
n = 202 
n (%) 
Age   
18 to 19 35 (25.4) 61(30.5) 
20 32 (23.2) 59(29.5) 
21 23 (16.7) 42 (21.0) 
22 to 32 48 (34.8) 38 (19.0) 
Race   
Asian 6 (4.3) 8 (4.0) 
Black/African    American 9 (6.5)  26 (12.9) 
White 118 (85.5) 163(80.7) 
Unknown  5 (3.6) 5 (2.5) 
Recruitment Setting   
Student Health Center  107 (77.5) 114 (56.4) 
Psychology Class  31 (22.5) 88 (43.5) 
Relationship Status   
 Not dating  38 (27.5) 43 (21.3) 
Dating no specific partner, single, never married  38 (27.5) 38 (18.8) 
Dating 1 steady partner (not living together)  50 (36.2) 102 (50.5) 
Married, dating 1 steady partner (living together)  12 (8.7) 19 (9.4) 
No. Partners   
    0 31 (23.0) 41 (20.4) 
    1 22 (16.3) 39 (19.4) 
    2 to 5 46 (34.1) 81 (40.3) 
    More than 5 36 (26.7) 40 (19.9) 
Knowledge   
    2 or 3 questions correct  30 (21.7) 84 (41.6) 
    0 or 1 questions correct 108 (78.3) 118 (58.4) 
Perceived Knowledge   
    Extremely or Very  18 (13) 39 (19.6) 
    Somewhat  41 (29.7) 89 (44.7) 
    Not at all  79 (57.2) 71 (35.7) 
Ever had an STD (yes, 9.4%) 9 (6.5) 23 (11.4) 
Ever had HPV (yes, 6.8%) 9 (39.1) 14 (60.9) 
Ever had GW (yes, 1.2%) 2 (50.0) 2 (50.0) 
Note. STD = Sexually Transmitted Diseases; HPV = Human papillomavirus; 
GW = Genital warts 
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 3.2 FACTORS ASSOCIATED WITH VACCINE ACCEPTANCE 
Several factors were significantly associated with intention to receive the vaccine in the overall 
sample (see Table 2).  These factors include ever having an STD, having someone close to 
him/her have HPV, having been sexually experienced, and having more partners.  Of those who 
have ever had an STD, 96.9% would accept the vaccine compared to 82.8% of those who never 
had an STD (p < .05).  Of those who had someone close to him/her have HPV, 94% would 
accept the vaccine compared to 85.3% of those who either did not know anyone close to them 
who had HPV and 76.7% of those who responded they did not know if someone close had HPV 
(p < .01).  Seventy-one percent of those who had no sexual partners would accept the vaccine, 
82.0% of those with one lifetime partner, 87.4% of those with 2 to 5 lifetime partners, and 93.4% 
of those with more than 5 partners would accept the vaccine (p = .001).   
The more HPV knowledge a person perceived him or herself as having, the more 
knowledge questions one answered correctly, both of which were significantly associated with 
accepting the vaccine.  Ninety-five percent of those who perceived themselves as “extremely” or 
“very” knowledgeable about HPV would accept the vaccine, 89.9% of those who perceived 
themselves as “somewhat”, and 77.3% of those “not at all” knowledgeable of HPV would accept 
the vaccine (p < .01).  Seventy-nine percent of those getting zero of the knowledge questions 
correct accepted the vaccine, 78.2% of those who got one correct, 94.4% of those answering 2 
correctly, and 100% of those answering all three questions correctly would accept the vaccine (p 
= .001).   
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Greater perceived risk was also associated with an increased likelihood of intention to 
receive the vaccine. Seventy-five percent of those answering “0 to 20%” for perceived risk of 
acquiring HPV at some point in their life would accept the vaccine, while 88.8% of those 
answering “21 to 60%” and 98.2% of those answering “61 to 100%” would accept the vaccine (p 
< .001).  Seventy-eight percent of those not dating, married, or living with someone would 
accept the vaccine, and 87.3% of those dating one steady partner, or no specific partner would 
accept the vaccine (p < .05).  Vaccine acceptance was not found to be significantly associated 
with age, race, recruitment setting, ever having HPV or genital warts, or perceived severity of 
HPV.   
Other factors found to make the participant “much more likely to accept the vaccine” 
were having a free vaccine (65.0%) and a doctor’s recommendation (42.4%).  Having to pay $50 
for the vaccine made 63.3% of participants “much less likely to accept the vaccine”.  People 
whose spouse (29.7%), parent (24.1%), or friend (18.5%) recommended the vaccine were “much 
more likely to accept the vaccine”.  
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Table 2 Accept Vaccine that Prevents Against both Cervical Cancer and Genital Warts 
 Extremely or Somewhat Likely 
 n (%) 
P 
value 
Gender   0.006
Male ( n =138) 107 (77.5)  
Female ( n =202) 179 (88.6)  
Age   0.814
18 to 19 (n =96) 83 (86.5)  
20 (n =91) 75 (82.4)  
21 (n =65) 56 (86.2)  
22 to 32 (n = 86) 71 (82.6)  
Race   0.176
Asian (n =14) 12 (85.7)  
AA (n =35) 25 (71.4)  
White (n =281) 241 (85.8)  
Unknown (n =10) 8 (80.0)  
Recruitment Setting  0.058
  Student Health Center 192 (86.9)  
Psychology Class 94 (79.0)  
Knowledge T/F   0.001
0 correct (n =93) 73 (78.5)  
1 correct (n = 133) 104 (78.2)  
2 correct (n =89) 84 (94.4)  
3 correct (n =25) 25 (100)  
Perceived knowledge   0.005
Extremely / Very (n =57) 54 (94.7)  
Somewhat (n =130) 113 (86.9)  
Not at all (n =150) 116 (77.3)  
Current Relationship Status  0.023
Not dating, married, or living with someone (n = 112) 87 (77.7)  
Dating 1 partner or no specific partner (n = 228) 199 (87.3)  
# of Sex partners   0.001
0 (N =72) 51 (70.8)  
1 (n =61) 50 (82.0)  
2 to 5 (n =127) 111 (87.4)  
More than 5 (n =76) 71 (93.4)  
Ever STD  0.038
Yes (n =32) 31 (96.9)  
No (n =308) 255 (82.8)  
Ever HPV  0.116
Yes (n =23) 22 (95.7)  
No (n =316) 263 (83.2)  
Ever GW  0.380
Yes (n =4) 4(100.0)  
No (n = 334) 280 (83.8)  
Anyone close HPV  0.007
Yes (n =67) 63 (94.0)  
No (n =156) 133 (85.3)  
Don’t Know (n=116) 89 (76.7)  
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Table 2 (continued) 
Perceived Risk  0.000
0 to 20% (n =158) 119 (75.3)  
21 to 60% (n =125) 111 (88.8)  
61 to 100% (n =56) 55 (98.2)  
Perceived severity of HPV  0.730
Worst thing that could happen 14 (77.8)  
Extremely upset 120 (84.5)  
Very upset 95 (82.6)  
Somewhat upset 56 (87.5)  
Not at all upset 0  
Note. STD = Sexually Transmitted Diseases; HPV = Human papillomavirus; GW = 
Genital warts 
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 3.3 GENDER COMPARISONS 
When examined by gender differences emerged (see Figure 1).  Males were more likely to accept 
the vaccine if it prevented both genital warts and cervical cancer, rather than one for cervical 
cancer alone (77.5% vs. 34.1%; p < .001).  Females were significantly more likely than men to 
accept an HPV vaccine that prevented both genital warts and cervical cancer (88.6% vs. 77.5%; 
p < .01).   
Men who were married, living with someone, or not dating were significantly less likely 
to accept the vaccine than those dating one partner or no specific partner (64.0% vs. 85.2%; p < 
.01).  Men who have had no sexual partners were significantly less likely to accept the vaccine 
compared to those with five or more partners (51.6% vs. 88.9%, p < .001).   Lastly, men who 
have ever had an STD were significantly more likely to accept the vaccine than those who never 
had an STD (100% vs. 80.4%; p < .05).   
Concerning women, answering two or three of the three knowledge questions correctly 
was significantly associated with accepting the vaccine compared to getting none or one correct 
(97.6% vs. 82.2%; p < .001).  Both men and women with higher perceived risk of getting HPV 
were more likely to receive the vaccine; those who answered they were “61 to 100%” likely to 
get HPV some point in their life were significantly more likely to get an HPV vaccine than those 
who felt they were only “0 to 20%” likely to get HPV (men, 93.3% vs. 68.7%, p < .05; women, 
100% vs. 80.2%, p< .01).  Intention to receive the vaccine was not significantly associated with 
age or race after stratifying by gender. 
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Figure 1  Proportion of university men and women who reported they would be “somewhat likely” or 
“extremely likely” to accept an HPV vaccine if it prevented various conditions. 
 
In the multivariate regression, both men and women were significantly more likely to 
accept an HPV vaccine if they had more than five sexual partners and higher HPV knowledge 
(see Table 3). Participants having more than five partners were about four times more likely than 
those having no partners to accept the vaccine (OR = 4.43; 95% CI = 1.36, 14.39).  Participants 
answering two or three of the three knowledge questions correctly were about three times more 
likely to get the vaccine as compared to those answering no or only one knowledge question 
correctly (OR = 3.59; 95% CI = 1.3, 9.93).  After stratifying by gender, women who answered 
two or three knowledge questions correctly were significantly more likely to accept the vaccine 
(OR = 8.17; 95% CI = 1.57, 42.61) and women who were ages 18 to 19 were significantly more 
 29 
likely than those 22 to 32 years old (OR = 5.36; 95% CI = 1.02, 28.04).  Though not significant, 
those who were ages 20 and 21 were more likely than those 22 to 32 years old (OR = 5.08; CI = 
.95, 27.12; OR = 1.78; CI = .39, 8.18, respectively).  Non-white women were almost half as 
likely as whites (OR = 0.2; 95% CI = 0.06, 0.63) to accept the vaccine.   Men who had one or 
two partners were about five times more likely (OR = 5.13; 95% CI = 1.27, 20.67), those with 
three to five partners were about 14 times more likely (OR = 14.14; 95% CI = 3.48, 57.37), and 
those with more than five partners (OR = 9.34; 95% CI = 2.22, 44.53) were nine times more 
likely than those with no partners to accept the vaccine.    
 
Table 3 Binary Logistic Regression of HPV Vaccination Acceptability 
 Overall Male Female 
Gender (female) 1.94 (.99, 3.77) --------- -------- 
Age    
   18 to19 2.36 (.89, 6.28) 1.56 (.39, 6.24) 5.36 (1.02, 28.04) 
   20 1.31 (.53, 3.24) .4 (.11, 1.41) 5.08 (.95, 27.12) 
   21 1.63 (.59, 4.52) 4.9 (.73, 32.86) 1.78 (.39, 8.18) 
   22 to 32 --------- --------- --------- 
Race (non- 
white/unknown) 
 
.62 (.28, 1.37) 
 
2.45 (.55, 10.98) 
 
.2 (.06, .63) 
# partners    
   0 --------- --------- --------- 
   1 to 2 1.65 (.66, 4.08) 5.13 (1.27, 20.67) .57 (.12, 2.83) 
   3 to 5 2.30 (.99, 5.35) 14.14 (3.48, 57.37) .51 (.13, 2.02) 
   More than 5 4.43 (1.36, 14.39) 9.34 (2.22, 44.53) 3.16 (.27, 36.92) 
Knowledge ( 2 or 3 
   correct) 
 
3.59 (1.30, 9.93) 
 
1.87 (.42, 8.27) 
 
8.17 (1.57, 42.61) 
Risk of HPV    
   0 to 20% --------- --------- --------- 
   21 to 60% 2.02 (.96, 4.25) 1.84 (.62, 5.47) 5.47 (1.39, 21.49) 
   61 to 100% 7.51 (.94, 60.1) 7.88 (.67, 92.52) * 
* Not put in model because 100% of women who answered 61 to 100% chose to take the 
vaccine 
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4.0  DISCUSSION 
This study suggests that in order to enhance the success and uptake of an HPV vaccine, 
promotional strategies and educational campaigns need to be specific with regard to gender, and 
should be tailored according to characteristics such as sexual experience, relationship status, and 
knowledge.   
This study’s results suggest that intention to receive an HPV vaccine is high among this 
cohort of university men and women, though slightly higher in women, supporting the first 
hypothesis.  Findings also suggest that potential vaccine attributes, particularly prevention 
against both genital warts and cervical cancer, notably influence intention to receive the vaccine 
among both young men and women, though not in relation to age as was stated in the second 
hypothesis.  Men in particular are significantly more likely to intend to get the HPV vaccine 
when it is described as preventing both cervical cancer and genital warts versus one that prevents 
against cervical cancer alone, as was stated it the third hypothesis.  This implies that the wording 
used in the promotion of the vaccine may play a significant role in how the vaccine is perceived, 
especially due to the previously mentioned finding that physicians are more likely to recommend 
the vaccine if it prevents cervical cancer and genital warts versus one that prevents cervical 
cancer alone (Riedesel et al., 2005).   This information can aid in the decision-making process of 
the current policy debate on whether to emphasize the benefits of the vaccine in terms of both 
cancer and STD prevention, versus placing emphasis on the prevention of cancer only.   
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 These findings also reveal that gender differences in intention to receive the vaccine do 
exist, and that overall, students who are dating, sexually experienced, have had more sexual 
partners, or have ever had an STD have higher intention to receive the vaccine.  Higher 
knowledge in terms of HPV, and consequently an increase in perceived risk of acquiring an HPV 
infection, also leads to increased intention to receive the vaccine.  Though age is not significantly 
related to intention to receive the vaccine in regards to specific vaccine attributes, the regression 
analysis reveals that younger women are more likely to be interested in getting the vaccine 
compared to older women.  Each of these results may help determine how the vaccine should be 
promoted to maximize vaccine uptake.  
The findings that sexually inexperienced individuals are less likely to accept an HPV 
vaccine has implications that need to be addressed since these are the very people who should be 
targeted to receive the vaccine given that they are least likely to already be infected with the 
disease.  Recommendations by the FDA and ACIP have been made to encourage vaccination 
before the initiation of sexual activity because vaccinating individuals before they become 
sexually active is most effective in preventing the acquisition of HPV (Kaiser Family 
Foundation, 2006).  This means it is imperative to educate adolescent and young adults about 
HPV even if they are not sexually active since they may be less likely to agree to receive the 
vaccine.  The results show that education can increase the likelihood of accepting the vaccine as 
those who were more educated on HPV were more likely to accept the vaccine.  
Previous research has shown that physician recommendation is one of the strongest 
factors that contribute to vaccine acceptability (Rosenthal, Kottenhahn, Biro, & Succop, 1995; 
Zimet, Mays, Winston, et al., 2000).  It is also important to note here that individuals in this 
study were much more willing to receive the vaccine should their doctor recommend it, which 
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points out the pivotal role health care providers play in educating individuals about HPV and 
encouraging them to receive the vaccine.  Vaccine recommendations among physicians has been 
found to be high, depending on factors such as patient’s age, gender, sexual history, and vaccine 
efficacy (Raley, Followwill, Zimet, & Ault, 2004; Riedesel, et al., 2005).  Therefore, healthcare 
providers must be informed about their pivotal role in the decision making process for many 
individuals as well as vaccine safety, efficacy and consequences of an HPV infection.   
The data presented here suggest that insurance coverage for the vaccine would 
significantly increase actual vaccine acceptance.  These finding are similar to that of Hoover, 
Carfioli, and Moench (2000), who found that only 15% of respondents would be extremely likely 
to pay for an HPV vaccine if the costs were not covered by insurance, and 31.7% would be either 
somewhat or extremely unlikely to pay for an HPV vaccine.  
A vaccine protecting against the most common types of HPV will not only improve the 
health of millions of women, but also reduce the health care costs associated with this disease.  
One study found that if a vaccine that was 75% effective in preventing high-risk HPV infections 
were administered to two million 12-year-old girls, it would prevent 224,255 infections, 3,317 
cases of cancer, and 1,340 cervical cancer-related deaths (Sanders & Taira, 2003).  Another 
study predicted that a vaccine preventing HPV types 16 and 18 would decrease cervical cancer 
cases associated with these two types by 95% (Taira, Neukermans, & Sanders, 2004).  Baer, 
Allen, and Braun (2000) predicted that vaccinating women only would be 68% as effective as 
vaccinating both genders. It is expected that the vaccine would not only be effective 
economically by reducing healthcare costs, but also by reducing the emotional burden of anxiety, 
fear, and embarrassment caused by a diagnosis with genital warts or an abnormal Pap test.   
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These benefits of vaccination are obvious for the developed world.  However, women in 
developing countries may benefit even more.  In many developing countries, cervical cancer is 
the leading cause of death and often screening programs are very difficult to implement and 
maintain.  Vaccine administration is expected to be cost-effective, though issues still do exist 
such as acceptance and most importantly having the necessary infrastructure available for 
providing access to all three shots (Goldie, et al., 2004).  
The findings presented here correspond with those of other researchers, though with 
some differences.  One study found that the disease targeted by the vaccine (i.e., genital warts or 
cervical cancer) did not appear to play a key role in evaluation of the vaccine, though these 
findings were based on interviews with 40 adolescent and adult women (Zimet, Mays, Winston, 
et al., 2000).  Another study of 60 women ages 15 to 28 found that they preferred a vaccine that 
protected against 70% of cancer and 100% of genital warts to one that protected against 85% of 
cancer only.  Concern about cervical cancer did not entirely overshadow apprehensions about 
other HPV infections such as genital warts as over half of the respondents were equally 
concerned about both infections and 7% were more concerned about genital warts. Most 
respondents preferred a vaccine that protected against genital warts even if coverage against 
cervical cancer was reduced (Hoover, Carfioli, & Moench, 2000).   
Other research found that sexual experience and an increased number of sexual partners 
increased hypothetical vaccine acceptance, while race and gender did not (Boehner, Howe, 
Bernstein, & Rosenthal, 2003; Kahn, Rosenthal, Hamann, & Bernstein, 2003).  Boehner and 
colleagues (2003) concluded that presenting the vaccine as preventing sexually related problems, 
instead of reproductive problems, does not significantly affect or deter vaccine acceptance.   
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5.0  CONCLUSIONS 
The development and approval of an HPV vaccine provides great potential for improving the 
health of millions of women, as well as men, but the key to success is in the administration of 
this vaccine.  Focusing on women alone undermines the significance of HPV infection for men 
and downplays the fact that men are major players in transmission of the virus.  Preventing the 
transmission of HPV requires both men and women to be cognizant of the infection and the 
complexity of prevention tactics.  Public health initiatives that want to facilitate HPV vaccine 
administration may be more successful if programs are designed to educate both sexes about the 
infection, the vaccine, and HPV-related complications. 
Limitations of this study include the fact that it is based on a hypothetical vaccine, though 
intention is often associated with actual behavior (Glanz, Rimer, & Lewis, 2002).  In addition, 
cost was not assessed directly since this study was conducted before the vaccine was approved 
by the FDA and the cost of the vaccine was not known yet.  Thus, the survey question assessing 
cost asked about paying $50 for the vaccine, when in reality the vaccine will cost about $360.  
Other limitations include the difference in the number of men and women, a relatively 
small number of non-white participants, and the use of convenience sampling involving men and 
women from only one large university.  Another limitation is the small number of students 
reporting having same sex partners, thus not allowing the examination of vaccine acceptability 
among gay men or lesbian women, which is an additional public health challenge that is not well 
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understood. Additionally, those individuals who were willing to fill out the survey while waiting 
in the Student Health Center may have been different from those who refused.  Those who were 
willing may have had a higher interest in the topic, and felt more comfortable answering 
questions regarding sexual and reproductive health.  Those who refused may have been less 
educated about HPV, or their own history may have made them less comfortable with the topic.  
The very fact that the students were recruited in a health center may make them different from 
others as they may take a more active role in their healthcare, possibly explaining why the study 
sample consisted of more women than men. Though the generalizability of these results may be 
limited, the findings have implications for future research as well for the design and 
implementation of a vaccine administration plan.    More studies are needed at various colleges 
of different sizes and in different areas, as well as with individuals of the same age who are not 
students.  Now that the vaccine is becoming available, researchers will also want to determine 
who is actually receiving the vaccine and the reasons why or why not.  
An HPV vaccination programs must still overcome many barriers.  One major barrier to a 
successful HPV vaccine administration program is the price of the vaccine.  At $360 for three 
doses, this vaccine is one of the most costly.  The CDC’s Advisory Committee on Immunization 
Practices expects the cost of the vaccine to be covered by most federal and private insurance 
companies, but this is no help to those who are uninsured or underinsured.  However, the federal 
Vaccines for Children Program will provide the vaccine free for disadvantaged children under 
the age of 19 who are uninsured, on Medicaid, Alaska Natives or American Indians (CDC, 
2006c).  Other barriers include identifying appropriate candidates, determining if and when 
boosters will be needed in case immunity wanes over time, and how health professionals can 
overcome the potential individual, parental, and social barriers to vaccine acceptance.  
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One strategy to promoting the vaccination would be to perform universal vaccination so 
that no one feels stigmatized.  Most health care professional associations develop their own 
policies on the recommendations made by the ACIP, though after the ACIP makes the 
recommendations, it is up to the state to decide whether the vaccine will be mandated for 
children upon entry into school or if Medicaid will cover the cost of the vaccine.  Should a state 
decide to require vaccination upon entering school, legal exemptions due exist on the basis of 
medical, religious, or philosophical grounds, which also vary from state to state (CDC, 2006d; 
National Vaccine Information Center, 2006).  As is the case with most vaccinations of 
individuals 18 and under, parental consent is required.  This is a dilemma as most states will 
provide family planning and STD preventive services to young adults without parental consent.  
The facilities that do so may find themselves in a quandary as they will not be able to provide 
their patients with an effective form of STD prevention. 
Extensive efforts must also be made to educate the public about the pervasiveness of 
HPV and advantages of vaccination.  Thus, if both men and women believe they are at risk for 
becoming infected with HPV, and perceive HPV infection as severe, they may be more likely to 
receive a vaccine that prevents HPV.  These conclusions speak to the importance of finding 
innovative ways to educate young men and women, no matter the age and sexual experience, 
about the prevalence and consequences of HPV.   
Lastly, it is important to note that although an effective vaccine is a major development in 
the prevention of HPV and cervical cancer, it should not replace other prevention strategies such 
as routine cancer screening and practicing safer sex. Women should continue to get Pap tests as 
the vaccine will not protect against all types of HPV; thus 30% of cervical cancers and 10% of 
genital warts will not be prevented.  Rather than replacing previous cervical cancer prevention 
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programs, the administration of an HPV vaccine at the primary prevention level should lead 
health professionals to re-examine secondary prevention efforts such as the existing screening 
procedures and guidelines.  
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APPENDIX A 
EXAMPLE SURVEY 
The purpose of this research study is to determine the acceptability of the HPV (Human 
Papillomavirus), vaccine among university students.  For that reason, we will be surveying 
University of Pittsburgh students and asking them to complete a brief (approximately 10 
minutes) questionnaire.  If you are willing to participate, our questionnaire will ask about your 
background (e.g., race, ethnicity, age, years of education), as well as your feelings concerning 
the HPV vaccine.  There are no foreseeable risks associated with this project, nor are there any 
direct benefits to you.  You will not be paid for your participation, although you will receive a $1 
PA lottery ticket as a token of our appreciation for completing this survey.  This is an entirely 
anonymous questionnaire, and so your responses will not be identified in any way.  All responses 
are confidential, and results will be kept under lock and key.  Your participation is voluntary, and 
you may withdraw from this project at any time.  This study is being conducted by Melissa 
Jones, who can be reached at 412.901.3073 or maj17@pitt.edu, if you have any questions. 
 
                         You must be at least 18 to complete this survey. 
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Thank you for taking the time to take this survey.  Your answers are very important to us. 
 
HPV is a sexually transmitted virus that can cause genital warts or cancer.                           
 
1.   How knowledgeable would you describe yourself when it comes to Human Papillomavirus or 
HPV? 
⁯ Extremely        ⁯ Very              ⁯ Somewhat   ⁯Not at all 
Knowledgeable   knowledgeable      knowledgeable  knowledgeable 
                     
 
The following are some specific questions about an HPV vaccine.  Right now a vaccine for 
HPV in not available, but is in the clinical trial stage.  We are interested in how people might 
feel about these vaccines should we get them.  So for now, please pretend the vaccine is 
available.
 
 
2.  Have you ever been told that you have HPV? (1)  Yes        (2)  No    
 
3.  Have you ever been told that you have genital warts?    (1)  Yes        (2)  No  
 
4.  Has anyone that you were close to ever had HPV (family, friends, significant others)? 
     (1)  Yes        (2)  No   (3) Don’t Know 
 
 
5.   If you do not get an HPV vaccine, what do you think your chances are of getting HPV 
sometime in your life (or in the future)?  
(1) 0 to 20%   (2) 21-40%         (3) 41-60%            (4) 61-80%           (5) 81%-100%  
 
 
6.  How likely is it that you would get a complication (i.e. warts or an abnormal Pap smear) from 
HPV if you became infected with it? 
(1) 0 to 20%   (2) 21-40%         (3) 41-60%            (4) 61-80%           (5) 81%-100%  
 
 
7.  How upset would you be if you were told that you: 
 
a)  Have genital HPV but you have no symptoms? 
(1) Worst thing         (2)Extremely        (3) Very          (4) Somewhat         (5) Not at all  
that could happen        upset            upset               upset           upset 
 
b)  Have genital warts? 
(1) Worst thing         (2)Extremely        (3) Very          (4) Somewhat         (5) Not at all  
that could happen        upset            upset               upset           upset 
 
 
8.  How severe do you think genital HPV infection is for yourself? 
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(1) Extremely       (2) Very      (3) Severe       (4) Somewhat  (5) Not at all 
 severe          severe                severe             severe 
 
9.  How severe do you think genital HPV infection is for men? 
(1) Extremely       (2) Very      (3) Severe       (4) Somewhat  (5) Not at all 
 severe          severe                severe             severe 
 
10.  How severe do you think genital HPV infection is for women? 
(1) Extremely       (2) Very      (3) Severe       (4) Somewhat  (5) Not at all 
 severe          severe                severe             severe 
 
 
11.  Please state whether you agree or disagree with the following statements: 
 
 Strongly 
agree 
Agree Neutral Disagree Strongly 
Disagree 
a. HPV is not serious enough for a 
vaccine. 
 
(1) (2) (3) (4) (5) 
b. HPV can be asymptomatic. 
 
 
(1) (2) (3) (4) (5) 
c. HPV can spontaneously resolve 
completely without treatment. 
 
(1) (2) (3) (4) (5) 
d. Greater than 50% of sexually active 
college students will have HVP once 
during college. 
(1) (2) (3) (4) (5) 
e. I can use condoms less with my 
partners if I get an HPV vaccine. 
 
(1) (2) (3) (4) (5) 
f. I may get HPV as a result of the 
vaccine. 
 
(1) (2) (3) (4) (5) 
g. Getting the HPV vaccine would 
make me sick. 
 
(1) (2) (3) (4) (5) 
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12. Assuming the HPV vaccine was available now, how likely would you be to get the 
vaccine if: 
 
 Extremely 
likely 
Somewhat 
likely 
Unsure Somewhat 
unlikely 
Extremely 
unlikely 
a.  It prevented all HPV 
 
 
 
(1) (2) (3) (4) (5) 
b.  It prevented cervical 
cancer in women, but did not 
prevent genital warts 
(1) (2) (3) (4) (5) 
c.  It prevented genital warts, 
but did not prevent cervical 
cancer in women 
(1) (2) (3) (4) (5) 
d.  It prevented both genital 
warts and cervical cancer 
 
(1) (2) (3) (4) (5) 
Would the following potential features make you less likely or more likely to 
get an HPV vaccine? 
 
 
 Much 
less 
likely to 
get 
Slightly 
less 
likely to 
get 
Neutral Slightly 
more 
likely to 
get 
Much 
more 
likely to 
get 
13.  Having to pay $50 for the HPV 
vaccine myself  
(1) (2) (3) (4) (5) 
14.  Having the HPV vaccine be free  
 
(1) (2) (3) (4) (5) 
15.  The HPV vaccine would work in only 
70% of persons 
(1) (2) (3) (4) (5) 
16.  Family or friends would know that I 
got the HPV vaccine 
(1) (2) (3) (4) (5) 
17.  The HPV vaccine was recommended 
to me by my doctor 
(1) (2) (3) (4) (5) 
18. The HPV vaccine was recommended to 
me by my spouse/partner 
(1) (2) (3) (4) (5) 
19.  The HPV vaccine was recommended 
to me by my friends 
(1) (2) (3) (4) (5) 
20. The HPV vaccine was recommended to 
me by my parents 
(1) (2) (3) (4) (5) 
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THIS PAGE IS FOR WOMEN ONLY.  MEN PLEASE GO 
 TO THE NEXT PAGE.    
 
21. Have you ever had an abnormal Pap smear?   (1)  Yes        (2)  No 
 
 
22.  Have you ever had a colposcopy? (1)  Yes        (2)  No 
 
 
23.  Have you ever had treatment for dysplasia (e.g. excision, LEEP)?  
(1)  Yes        (2)  No   (3) Don’t Know 
 
 
24.  Has anyone in your immediate family (e.g. Parents, Siblings) ever had cervical cancer?  
(1)  Yes       (2)  No  (3)  Don’t know        
 
 
24.  How upset would you be if you were told that you have an abnormal Pap smear due to 
HPV? 
(1) Worst thing         (2)Extremely        (3) Very          (4) Somewhat         (5) Not at all  
that could happen        upset            upset               upset           upset 
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Finally, please tell us a little bit about yourself.     
  
25. Current Age:  _______ (years) 
 
26. Sex/Gender:     (1) Male        (2) Female 
 
27. Current year in College: 
(1) Freshman   (2) Sophomore   (3) Junior   (4) Senior    5) Grad Student     (6) Other 
 
28. Ethnicity  (please check one):     
(1) Non-Hispanic        (2) Hispanic or Latino      (3) Unknown or prefer not to answer       
          
29. Race (please circle all that apply):   
(1) American Indian or Alaska Native         (4) Black or African American 
(2) Asian              (5) White 
(3) Native American or Other Pacific Islander        (6) Unknown or prefer not to  
       answer 
    
30. Current relationship status (please check one): 
(1) Not dating           (5) Single, never married 
(2) Dating, no specific partner                 (6) Married       
(3) Dating, one steady partner (not living together)  (7) Divorced/Separated       
(4) Dating, one steady partner (living together)     (8) Widowed 
  
31. Have you ever had: 
a.)  vaginal or anal sex?   (1) Yes   (2) No 
b.)  oral sex?       (1) Yes   (2) No 
 
If yes to either question, please continue on.  If no to both questions, please stop.   
Thank you very much for your time.  We really appreciate it. 
 
32. You are sexually experienced with (circle only one): 
(1) The opposite sex  (2) The same sex   (3) Both 
 
 
33. In your life how many different people have you had sexual intercourse with?  _______ 
 
34. Have you ever had a sexually transmitted disease (Chlamydia, Trichomonas (trich), 
Gonorrhea (GC), Pubic lice/”crabs”, Genital herpes, Syphilis, Condyloma (genital warts), 
Human papilloma virus (HPV))?    (1) Yes   (2) No 
  
 
That’s it!  You’re done!  We appreciate your willingness to answer these 
questions.  
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